Switch View
© Globe Newswire
07.10.2025
ISIN: CA4990531069
Knight Therapeutics Inc
GUD
LISTED
TSX
Knight Therapeutics Announces Relaunch of ORGOVYX® in Canada
News Preview
MONTREAL, Oct. 07, 2025 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc., (TSX: GUD) ("Knight") a pan-American (ex-USA) specialty pharmaceutical company, announced today that it has relaunched ORGOVYX® (relugolix) in Canada....
Themefolio
Profiler
Peergroup
© Globe Newswire
07.10.2025
ISIN: US0080642061
Jade Biosciences Inc
JBIO
LISTED
NASDAQ
Jade Biosciences Announces JADE201, a Potentially Best-in-Class Half-Life Extended Afucosylated Anti-BAFF Receptor Monoclonal Antibody in Development for Autoimmune Diseases
News Preview
Jade Biosciences Announces JADE201, a Potentially Best-in-Class Half-Life Extended Afucosylated Anti-BAFF Receptor Monoclonal Antibody...
Themefolio
Profiler
Peergroup
© Globe Newswire
07.10.2025
ISIN: US0080642061
Jade Biosciences Inc
JBIO
LISTED
NASDAQ
Jade Biosciences Announces $135 Million Private Placement
News Preview
Jade Biosciences Announces $135 Million Private Placement...
Themefolio
Profiler
Peergroup
Worth to know
20.10.2025
Short Selling Radar
USA, Europe, Asia
Track Short Selling Activities worldwide
Knowing what matters
Leerverkaufsstatistiken, Hedge-Fund Aktivitäten und viele weitere nutzerwertige Informationen benutzerfreundlich aufbereitet
© Globe Newswire
07.10.2025
ISIN: US05464T1043
Axsome Therapeutics Inc
AXSM
LISTED
NASDAQ
Axsome Therapeutics to Report Third Quarter 2025 Financial Results on November 3
News Preview
NEW YORK, Oct. 07, 2025 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) disorders, today announced it will report its financial results for the third quarter of 2025 on Monday, November 3, 2025, before the opening of the U.S. financial mar...
Themefolio
Profiler
Peergroup
Swarmalpha i/o · The Event Futures Prediction X
20.10.2025
© Globe Newswire
07.10.2025
ISIN: US35168W1036
Fractyl Health Inc
GUTS
LISTED
NASDAQ
Fractyl Health Announces Potent Preclinical Results from RJVA-002, a Dual GIP/GLP-1 Gene Therapy Candidate for Obesity
News Preview
RJVA-002 achieved ~30% weight loss at five weeks in a translational obesity model; weight loss not yet plateauedPreclinical results show that a single point-in-time treatment with RJVA-002 has the potential to achieve significant weight loss that can match or exceed best-in-class chronic drug therapy...
Themefolio
Profiler
Peergroup
© Globe Newswire
07.10.2025
ISIN: US00973Y1082
Akero Therapeutics Inc
AKRO
LISTED
NASDAQ
Akero Therapeutics to Present New Data from the Phase 2b SYMMETRY and HARMONY Studies of Efruxifermin at the 76th Annual AASLD The Liver Meeting® 2025
News Preview
SOUTH SAN FRANCISCO, Calif., Oct. 07, 2025 (GLOBE NEWSWIRE) -- Akero Therapeutics, Inc. (Nasdaq: AKRO), a clinical-stage company developing transformational treatments for patients with serious metabolic diseases marked by high unmet medical need, today announced two upcoming oral presentations and a poster presentation at the 76th Annual America...
Themefolio
Profiler
Peergroup
© Globe Newswire
07.10.2025
ISIN: US67576A1007
Ocular Therapeutix Inc
OCUL
LISTED
NASDAQ
Ocular Therapeutix™ to Participate in Upcoming Scientific Conferences
News Preview
BEDFORD, Mass., Oct. 07, 2025 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ: OCUL, “Ocular”), an integrated biopharmaceutical company committed to redefining the retina experience, today announced participation in several upcoming scientific conferences in October 2025....
Themefolio
Profiler
Peergroup
© Globe Newswire
07.10.2025
ISIN: US7867001049
Sagimet Biosciences Inc
SGMT
LISTED
NASDAQ
Sagimet Biosciences Announces Upcoming Presentation at AASLD—The Liver Meeting® 2025
News Preview
SAN MATEO, Calif., Oct. 07, 2025 (GLOBE NEWSWIRE) -- Sagimet Biosciences Inc. (Nasdaq: SGMT), a clinical-stage biopharmaceutical company developing novel therapeutics targeting dysfunctional metabolic and fibrotic pathways, today announced that analyses of the Phase 2b FASCINATE-2 study showing that denifanstat elicited fibrosis improvement in pa...
Themefolio
Profiler
Peergroup
© Newsfile
07.10.2025
ISIN: AU0000317281
Percheron Therapeutics Limited
PER
LISTED
ASX
Edison Issues Report on Percheron Therapeutics (PER)
News Preview
London, United Kingdom--(Newsfile Corp. - October 7, 2025) - Edison issues report on Percheron Therapeutics (ASX: PER)Percheron Therapeutics has reported final results from the Phase I dose escalation study of HMBD-002, its monoclonal antibody targeting VISTA, a novel immune checkpoint protein. The data confirmed the compound's favourable safety an...
Themefolio
Profiler
Peergroup
© Globe Newswire
07.10.2025
ISIN: US53635D2027
Liquidia Corp
LQDA
LISTED
NASDAQ
Liquidia Corporation to Host R&D Day in New York City on October 28, 2025
News Preview
MORRISVILLE, N.C., Oct. 07, 2025 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ: LQDA), a biopharmaceutical company developing innovative therapies for patients with rare cardiopulmonary disease, today announced that it will host a Research & Development Day (R&D Day) on Tuesday, October 28, 2025, in New York City which will be webcast...
Themefolio
Profiler
Peergroup
© Globe Newswire
07.10.2025
ISIN: US52886X1072
Lexeo Therapeutics Inc
LXEO
LISTED
NASDAQ
Lexeo Therapeutics Announces Progress in FDA Discussions for Accelerated Approval Pathway and Positive Interim Clinical Data for LX2006 in Friedreich Ataxia Cardiomyopathy
News Preview
Lexeo Therapeutics Announces Progress in FDA Discussions for Accelerated Approval and Positive Interim Clinical Data for LX2006 in FA Cardiomyopathy...
Themefolio
Profiler
Peergroup
© ACCESSWIRE
07.10.2025
ISIN: US49457M1062
Kindly MD, Inc.
NAKA
LISTED
NASDAQ
KindlyMD Announces Strategic Partnership with Antalpha and Intent to Establish $250 Million Convertible Debt Facility
News Preview
First Step in Broader Effort to Develop Innovative Financing Tools for the Bitcoin MarketCollaboration Launches Initial Treasury Financing Structure SALT LAKE CITY, UTAH / ACCESS Newswire / October 7, 2025 / KindlyMD, Inc. (NASDAQ:NAKA) ("KindlyMD" or "the Company"), a provider of integrated healthcare services and a Bitcoin tre...
Themefolio
Profiler
Peergroup
Advertisment
20.10.2025
© PR Newswire
07.10.2025
ISIN: US81684M1045
Semler Scientific Inc
SMLR
LISTED
NASDAQ
SMLR Investors Have Opportunity to Lead Semler Scientific, Inc. Securities Fraud Lawsuit with the Schall Law Firm
News Preview
LOS ANGELES, Oct. 6, 2025 /PRNewswire/ -- The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Semler Scientific, Inc. ("Semler" or "the Company") (NASDAQ: SMLR) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 1...
Themefolio
Profiler
Peergroup
© ACCESSWIRE
07.10.2025
ISIN: US74366E1029
Protagonist Therapeutics Inc
PTGX
LISTED
NASDAQ
Protagonist Announces New Icotrokinra Data in Ulcerative Colitis Showing Potential for a Standout Combination of Therapeutic Benefit and a Favorable Safety Profile in Once-daily Pill
News Preview
Icotrokinra met the primary endpoint of clinical response at all three doses, with 36.5% of patients treated achieving endoscopic improvement and 30.2% achieving clinical remission at the highest dose at Week 12 in the Phase 2b ANTHEM-UC studyThese data support the promise of a first-in-class targeted oral peptide that selectively blocks the IL-23...
Themefolio
Profiler
Peergroup
© BusinessWire
07.10.2025
ISIN: DE000BAY0017
Bayer AG
BAYN
LISTED
XETR
BlueRock Therapeutics reports positive 36-month results from Phase I trial of bemdaneprocel for treating Parkinson’s disease
News Preview
Bayer AG and its wholly owned, independently operated subsidiary BlueRock Therapeutics LP, a clinical stage cell therapy company, today announced positive 36-month data from exPDite, a Phase I clinical trial of bemdaneprocel, an investigational cell therapy for the treatment of Parkinson's disease (PD). The data were presented on October 6th at th...
Themefolio
Profiler
Peergroup
© ACCESSWIRE
07.10.2025
ISIN: CA58471K2020
Medicus Pharma Ltd.
MDCX
LISTED
TSX
Medicus Pharma Ltd. to Present at the Family Office Summit in Dubai, UAE
News Preview
EXECUTIVE CHAIRMAN & CEO OF MEDICUS TO PARTICIPATE IN A PANEL DISCUSSIONThe Summit theme "unlocking the $1 Trillion Wealth transfer in Dubai" PHILADELPHIA, PENNSYLVANIA / ACCESS Newswire / October 7, 2025 / Medicus Pharma Ltd. (NASDAQ:MDCX) ("Medicus" or the "Company"), a biotech/life sciences company focused on ad...
Themefolio
Profiler
Peergroup
© ACCESSWIRE
07.10.2025
ISIN: US87975F1049
Telomir Pharmaceuticals, Inc.
TELO
LISTED
NASDAQ
Telomir Pharmaceuticals Announces New Findings in a Prostate Cancer Model Demonstrating Telomir-1 Also Resets DNA Methylation of Tumor Suppressor Genes Implicated in Two of the Most Persistent Challenges in Oncology-Metastasis and Treatment Resistance
News Preview
Findings show that Telomir-1 restores the body's natural tumor suppressor defenses by reversing abnormal DNA methylation of MASPIN and RASSF1A - genes that help block invasion, limit metastasis, and improve chemotherapy responsiveness in aggressive prostate cancer models. MIAMI, FLORIDA / ACCESS Newswire / October 7, 2025 / Telomir Pharmaceuticals,...
Themefolio
Profiler
Peergroup
© Newsfile
07.10.2025
ISIN: NL0011832936
Cosmo Pharmaceuticals NV
COPN
LISTED
SIX
Cosmo Pharmaceuticals Announces Regulatory Approval of Winlevi(R) in South Korea
News Preview
Dublin, Ireland--(Newsfile Corp. - October 7, 2025) - Cosmo Pharmaceuticals N.V. (SIX: COPN), a global leader in AI-driven healthcare and specialty pharmaceuticals, today announced that the Ministry of Food and Drug Safety (MFDS) of the Republic of Korea has approved Winlevi® (clascoterone) cream 1% for the treatment of acne vulgari...
Themefolio
Profiler
Peergroup
© ACCESSWIRE
07.10.2025
ISIN: CA00143Y1034
AI-ML Innovations Inc.
AIML
LISTED
CSE
AIML Subsidiary NeuralCloud Solutions and Toronto Heart Centre Launch a Pilot Program to Test AI-Powered Holter ECG Reporting
News Preview
Pilot Evaluation: Toronto Heart Centre to conduct comparative testing of CardioYield™ for enhanced Holter ECG analysis and reporting efficiency.Clinical Workflow Impact: Study to measure time savings, throughput improvements, and analysis quality when using CardioYield™ versus current industry-standard software. TORONTO, ON, AB / ACCESS...
Themefolio
Profiler
Peergroup
© BusinessWire
07.10.2025
ISIN: US60855R1005
Molina Healthcare Inc
MOH
LISTED
NYSE
MOH Investors Have Opportunity to Lead Molina Healthcare, Inc. Securities Fraud Lawsuit with the Schall Law Firm
News Preview
The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Molina Healthcare, Inc. (“Molina” or “the Company”) (NYSE: MOH) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.
In...
Themefolio
Profiler
Peergroup
© BusinessWire
07.10.2025
ISIN: US60855R1005
Molina Healthcare Inc
MOH
LISTED
NYSE
Molina Healthcare, Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights – MOH
News Preview
The DJS Law Group reminds investors of a class action lawsuit against Molina Healthcare, Inc. (“Molina” or “the Company”) (NYSE: MOH) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.
Shareholders who purchased shares of MOH during the...
Themefolio
Profiler
Peergroup
© PR Newswire
07.10.2025
ISIN: KY61559X1045
MoonLake Immunotherapeutics
MLTX
LISTED
NASDAQ
MoonLake Immunotherapeutics Investigated for Securities Fraud Violations - Contact the DJS Law Group to Discuss Your Rights - MLTX
News Preview
LOS ANGELES, Oct. 6, 2025 /PRNewswire/ -- The DJS Law Group announces that it is investigating claims on behalf of investors of MoonLake Immunotherapeutics ("MoonLake" or "the Company") (NASDAQ: MLTX) for violations of the securities laws.
INVESTIGATION DETAILS: The investigatio...
Themefolio
Profiler
Peergroup
© PR Newswire
07.10.2025
ISIN: KY61559X1045
MoonLake Immunotherapeutics
MLTX
LISTED
NASDAQ
MLTX Investors Have Opportunity to Join MoonLake Immunotherapeutics Fraud Investigation with the Schall Law Firm
News Preview
LOS ANGELES, Oct. 6, 2025 /PRNewswire/ -- The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of MoonLake Immunotherapeutics ("MoonLake" or "the Company") (NASDAQ: MLTX) for violations of the securities laws....
Themefolio
Profiler
Peergroup
© PR Newswire
07.10.2025
ISIN: US23282W6057
Cytokinetics Inc
CYTK
LISTED
NASDAQ
Robbins LLP Reminds Cytokinetics, Inc. Investors of the Upcoming Lead Plaintiff Deadline in the Class Action Against CYTK
News Preview
SAN DIEGO, Oct. 6, 2025 /PRNewswire/ -- Robbins LLP reminds stockholders that a class action was filed on behalf of persons and entities that purchased or otherwise acquired Cytokinetics, Inc. (NASDAQ: CYTK) securities between December 27, 2023 and May 6, 2025. Cytokinetics is a biopharmaceutical company focused...
Themefolio
Profiler
Peergroup
© PR Newswire
07.10.2025
ISIN: US28176E1082
Edwards Lifesciences Corp.
EW
LISTED
NYSE
Rosen Law Firm Announces Investigation of Breaches of Fiduciary Duties by the Directors and Officers of Edwards Lifesciences Corporation - EW
News Preview
NEW YORK, Oct. 6, 2025 /PRNewswire/ -- Rosen Law Firm, a global investor rights law firm, continues to investigate potential breaches of fiduciary duties by the directors and officers of Edwards Lifesciences Corporation (NYSE: EW)....
Themefolio
Profiler
Peergroup
© PR Newswire
07.10.2025
ISIN: SE0010323311
BioArctic AB
BIOA B
LISTED
STO
Leqembi® Iqlik™ (lecanemab-irmb) maintenance treatment launched in the U.S.
News Preview
STOCKHOLM, Oct. 6, 2025 /PRNewswire/ -- BioArctic AB's (publ) (Nasdaq Stockholm: BIOA B) partner Eisai announced today that lecanemab-irmb subcutaneous injection (U.S. brand name: Leqembi Iqlik) is now available in the U.S. as a maintenance dosing regimen for the treatment of Alzheimer's disease (AD) in patients...
Themefolio
Profiler
Peergroup
© PR Newswire
07.10.2025
ISIN: SE0010323311
BioArctic AB
BIOA B
LISTED
STO
Leqembi® Iqlik™ (lecanemab-irmb) maintenance treatment launched in the U.S.
News Preview
STOCKHOLM, Oct. 6, 2025 /PRNewswire/ -- BioArctic AB's (publ) (Nasdaq Stockholm: BIOA B) partner Eisai announced today that lecanemab-irmb subcutaneous injection (U.S. brand name: Leqembi Iqlik) is now available in the U.S. as a maintenance dosing regimen for the treatment of Alzheimer's disease (AD) in patients...
Themefolio
Profiler
Peergroup
© ACCESSWIRE
06.10.2025
ISIN: US64051A1016
NeOnc Technologies Holdings Inc
NTHI
LISTED
NASDAQ
New to The Street to Broadcast Tonight on Fox Business 10:30 PM PST Featuring NeOnc Technologies, FLOKI, XION, Sharps Technology, and Aeries Technology
News Preview
NEW YORK CITY, NEW YORK / ACCESS Newswire / October 6, 2025 / New to The Street, one of America's longest-running business television brands, announces tonight's nationwide broadcast on Fox Business at 10:30 PM PST. The episode features exclusive interviews with NeOnc Technologies (NASDAQ:NTHI), FLOKI, XION, Sharps Technology (NASDAQ:STSS), and Aer...
Themefolio
Profiler
Peergroup
© Globe Newswire
06.10.2025
ISIN: US2697961082
Eagle Pharmaceuticals Inc
EGRX
LISTED
NASDAQ
Eagle Pharmaceuticals Announces Availability of Unaudited First Quarter 2025 Financial Statements
News Preview
WOODCLIFF LAKE, N.J., Oct. 06, 2025 (GLOBE NEWSWIRE) -- Eagle Pharmaceuticals, Inc. (OTCMKTS: EGRX) (the “Company” or “Eagle”) today announced that the Company’s unaudited financial statements for the three months ended March 31, 2025, are available at https://investor.eagleus.com/events-presentations....
Themefolio
Profiler
Peergroup
© BusinessWire
06.10.2025
ISIN: US2825591033
89Bio, Inc.
ETNB
LISTED
NASDAQ
89bio Investor Alert By The Former Attorney General Of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of 89bio, Inc. - ETNB
News Preview
Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of 89bio, Inc. (NasdaqGM: ETNB) to Roche Holding AG (OTC: RHHBY). Under the terms of the proposed transaction, shareholders of 89bio will receive $14.50 per share in cash at closing, plus a non-...
Themefolio
Profiler
Peergroup
© BusinessWire
06.10.2025
ISIN: US03073E1055
Cencora Inc
COR
LISTED
NYSE
Cencora Announces Date and Time for Fourth Quarter Fiscal 2025 Earnings Release
News Preview
Cencora, Inc. (NYSE: COR) today announced that it plans to release its results for the Fourth Quarter of Fiscal 2025 on Wednesday, November 5, 2025, prior to the opening of trading on the New York Stock Exchange. The Company will host a conference call to discuss the results at 8:30 a.m. ET on November 5, 2025.
Participating in the conference ca...
Themefolio
Profiler
Peergroup
© BusinessWire
06.10.2025
ISIN: US20603L1026
Concentra Group Holdings Parent, Inc.
CON
LISTED
NASDAQ
Concentra® to Announce Third Quarter 2025 Results on Thursday, November 6, 2025
News Preview
Concentra® Group Holdings Parent, Inc. (“Concentra”) (NYSE: CON) will release the financial results for its third quarter ended September 30, 2025, on Thursday, November 6, 2025, after the market closes.
Concentra will host a conference call regarding its financial results on Friday, November 7, 2025, at 9 a.m. Eastern Time. The conference call...
Themefolio
Profiler
Peergroup
© PR Newswire
06.10.2025
ISIN: US09062X1037
Biogen Inc
BIIB
LISTED
NASDAQ
Eisai and Biogen Announce U.S. Availability of LEQEMBI® IQLIK™ (lecanemab-irmb) Subcutaneous Injection Maintenance Dose for Treatment of Early Alzheimer's Disease
News Preview
New LEQEMBI CompanionTM program launched to expand helpful resources for patients throughout the treatment journey, including Nurse Educators who can provide patients with injection training, and an injection tracking tool and more
LEQEMBI IQLIK, approved by the U.S. FDA in August 2025, is the fi...
Themefolio
Profiler
Peergroup
© BusinessWire
06.10.2025
ISIN: US00857U1079
agilon health inc
AGL
LISTED
NYSE
agilon health Sets Date to Report Third Quarter 2025 Financial Results
News Preview
agilon health, inc. (NYSE: AGL), the trusted partner empowering physicians to transform health care in our communities, today announced that it will release financial results for the third quarter 2025 after market close on Tuesday, November 4, 2025 and host a conference call at 4:30 p.m. ET to discuss the results.
The conference call can be acc...
Themefolio
Profiler
Peergroup
© PR Newswire
06.10.2025
ISIN: US64125C1099
Neurocrine Biosciences Inc
NBIX
LISTED
NASDAQ
Neurocrine Biosciences Appoints Mike Sibley as Senior Vice President, General Manager of Neuropsychiatry Franchise
News Preview
SAN DIEGO, Oct. 6, 2025 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced the appointment of Mike Sibley as Senior Vice President and General Manager of the company's Neuropsychiatry franchise. Sibley, a proven leader with more than 20 years of commercial experience in the biopharmaceuti...
Themefolio
Profiler
Peergroup
© BusinessWire
06.10.2025
ISIN: US8523123052
STAAR Surgical Co
STAA
LISTED
NASDAQ
Yunqi Capital, One of STAAR Surgical Company’s Largest Shareholders, Reiterates Its Opposition to the Proposed Merger with Alcon
News Preview
Yunqi Capital Limited (together with its affiliates and the funds it advises, “Yunqi Capital”), an investment management firm and 5.1% shareholder of STAAR Surgical Company (“STAAR” or the “Company”) (NASDAQ:STAA), today released the following open letter reiterating its opposition to the proposed sale to Alcon Inc. (SIX/NYSE:ALC) on the terms ann...
Themefolio
Profiler
Peergroup
© BusinessWire
06.10.2025
ISIN: US68213N1090
Omnicell Inc
OMCL
LISTED
NASDAQ
Omnicell to Release Third Quarter 2025 Financial Results on October 30, 2025
News Preview
Omnicell, Inc. (Nasdaq:OMCL), a leader in transforming the pharmacy and nursing care delivery model, will release its financial results for the third quarter 2025, before market open on Thursday, October 30, 2025. The Company will host a conference call and webcast to discuss its financial results at 8:30 a.m. ET that same day.
All interested pa...
Themefolio
Profiler
Peergroup
© Globe Newswire
06.10.2025
ISIN: US26818M1080
Dyne Therapeutics Inc
DYN
LISTED
NASDAQ
Dyne Therapeutics Announces Additional One-Year Clinical Data Demonstrating Functional Improvement from Phase 1/2 ACHIEVE Trial of Zeleciment Basivarsen (DYNE-101) for Myotonic Dystrophy Type 1 (DM1)
News Preview
- Robust improvement demonstrated across diverse set of clinical measures -...
Themefolio
Profiler
Peergroup
© BusinessWire
06.10.2025
ISIN: US92532F1003
Vertex Pharmaceuticals Inc
VRTX
LISTED
NASDAQ
Vertex to Announce Third Quarter 2025 Financial Results on November 3rd
News Preview
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) will report its third quarter 2025 financial results on Monday, November 3, 2025, after the financial markets close. The company will host a conference call and webcast at 4:30 p.m. ET. To access the call, please dial (833) 630-2124 (U.S.) or +1 (412) 317-0651 (International) and reference the “Ve...
Themefolio
Profiler
Peergroup
© BusinessWire
06.10.2025
ISIN: US4834971032
Kalvista Pharmaceuticals Inc
KALV
LISTED
NASDAQ
KalVista Pharmaceuticals Presents New Data Highlighting the Potential of EKTERLY® (sebetralstat) to Transform On-Demand Hereditary Angioedema Treatment in Europe
News Preview
KalVista Pharmaceuticals, Inc. (Nasdaq: KALV) today announced new data from its KONFIDENT and KONFIDENT-S studies of EKTERLY® (sebetralstat), the first and only oral on-demand treatment for hereditary angioedema (HAE), presented at the 20th German Allergy Congress in Düsseldorf, Germany from October 2–4, 2025. Across multiple ePoster presentations...
Themefolio
Profiler
Peergroup
© BusinessWire
06.10.2025
ISIN: US4781601046
Johnson & Johnson
JNJ
LISTED
NYSE
Johnson & Johnson to Participate in the Guggenheim Securities 2nd Annual Healthcare Innovation Conference
News Preview
Johnson & Johnson (NYSE: JNJ) will present at the Guggenheim Securities 2nd Annual Healthcare Innovation Conference on Tuesday, November 11th, 2025. Management will participate in a Fireside Chat at 10:30 a.m. Eastern Time.
A live audio webcast of the presentation will be accessible through Johnson & Johnson’s Investor Relations website...
Themefolio
Profiler
Peergroup
© Globe Newswire
06.10.2025
ISIN: US4884452065
Zevra Therapeutics Inc
ZVRA
LISTED
NASDAQ
Zevra Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
News Preview
CELEBRATION, Fla., Oct. 06, 2025 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra, or the Company), a commercial-stage company focused on providing therapies for people living with rare disease, today announced that the Company has granted options to purchase an aggregate of 38,000 shares of the Company’s common stock (the “In...
Themefolio
Profiler
Peergroup
© PR Newswire
06.10.2025
ISIN: US53216B1044
LifeMD, Inc.
LFMD
LISTED
NASDAQ
LifeMD Deadline: LFMD Investors with Losses in Excess of $50K Have Opportunity to Lead LifeMD, Inc. Securities Fraud Lawsuit First Filed by The Rosen Law Firm
News Preview
NEW YORK, Oct. 6, 2025 /PRNewswire/ --
Why: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of LifeMD, Inc. (NASDAQ: LFMD) be...
Themefolio
Profiler
Peergroup
© BusinessWire
06.10.2025
ISIN: US60855R1005
Molina Healthcare Inc
MOH
LISTED
NYSE
MOH INVESTOR ALERT: Robbins Geller Rudman & Dowd LLP Announces that Molina Healthcare, Inc. Investors with Substantial Losses Have Opportunity to Lead the Molina Healthcare Class Action Lawsuit
News Preview
The law firm of Robbins Geller Rudman & Dowd LLP announces that purchasers or acquirers of Molina Healthcare, Inc. (NYSE: MOH) securities between February 5, 2025 and July 23, 2025, inclusive (the “Class Period”), have until December 2, 2025 to seek appointment as lead plaintiff of the Molina class action lawsuit. Captioned Hindlemann v. Molin...
Themefolio
Profiler
Peergroup
© Globe Newswire
06.10.2025
ISIN: FR0010417345
Dbv Technologies SA
DBV
LISTED
EURONEXT
DBV Technologies Announces Sale of approximately $30 million of ADSs Through its At-The-Market (ATM) Program on Nasdaq
News Preview
Châtillon, France, October 6, 2025...
Themefolio
Profiler
Peergroup
© Globe Newswire
06.10.2025
ISIN: US74112D1019
Prestige Consumer Healthcare Inc
PBH
LISTED
NYSE
Prestige Consumer Healthcare to Release Fiscal 2026 Second Quarter Earnings Results
News Preview
TARRYTOWN, N.Y., Oct. 06, 2025 (GLOBE NEWSWIRE) -- Prestige Consumer Healthcare Inc. (NYSE:PBH) today announced that it will issue its fiscal 2026 second quarter and first half earnings release on Thursday, November 6, 2025 before the opening of the market. The Company will host a conference call to discuss the results that same morning at 8:30 a...
Themefolio
Profiler
Peergroup
© Globe Newswire
06.10.2025
ISIN: US18914F1030
Clover Health Investments Corp
CLOV
LISTED
NASDAQ
Counterpart Health Expands Leadership to Accelerate Enterprise Partnerships and Regional Adoption of AI-Powered Platform Counterpart Assistant
News Preview
New VP Blaine Lindsey to Drive National Enterprise Growth; Gulf Region President Shannon Jacobs to Scale Operations in High-Need Markets New VP Blaine Lindsey to Drive National Enterprise Growth; Gulf Region President Shannon Jacobs to Scale Operations in High-Need Markets...
Themefolio
Profiler
Peergroup
© Globe Newswire
06.10.2025
ISIN: US09062X1037
Biogen Inc
BIIB
LISTED
NASDAQ
Eisai and Biogen Announce U.S. Availability of LEQEMBI® IQLIK™ (lecanemab-irmb) Subcutaneous Injection Maintenance Dose for Treatment of Early Alzheimer’s Disease
News Preview
New LEQEMBI Companion™ program launched to expand helpful resources for patients throughout the treatment journey, including Nurse Educators who can provide patients with injection training, and an injection tracking tool and more...
Themefolio
Profiler
Peergroup
© Globe Newswire
06.10.2025
ISIN: US09077A1060
Biomea Fusion Inc
BMEA
LISTED
NASDAQ
Biomea Fusion Announces Proposed Public Offering of Securities
News Preview
SAN CARLOS, Calif., Oct. 06, 2025 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. (“Biomea”) (Nasdaq: BMEA), a clinical-stage diabetes and obesity company, announced today that it has commenced an underwritten public offering of shares of its common stock and accompanying warrants to purchase shares of its common stock (or pre-funded warrants in lieu the...
Themefolio
Profiler
Peergroup
© Globe Newswire
06.10.2025
ISIN: US45258H1068
Immix Biopharma, Inc.
IMMX
LISTED
NASDAQ
Immix Biopharma to Present Abstract at the upcoming ASH 2025 Annual Meeting
News Preview
Los Angeles, CA, Oct. 06, 2025 (GLOBE NEWSWIRE) -- Immix Biopharma, Inc. (“ImmixBio”, “Company”, “We” or “Us” or ”IMMX”), the global leader in relapsed/refractory AL Amyloidosis, today announced that it will present a NXC-201 abstract at the upcoming American Society of Hematology (ASH) 67th Annual Meeting and Exposition to be held December 6-9,...
Themefolio
Profiler
Peergroup
© Globe Newswire
06.10.2025
ISIN: US81727U1051
Senseonics Holdings Inc
SENS
LISTED
XASE
Senseonics Announces Preliminary Unaudited Revenue for Third Quarter 2025 and Provides Business Update
News Preview
Preliminary unaudited revenue of $8.1 million for Q3 2025...
Themefolio
Profiler
Peergroup
© Globe Newswire
06.10.2025
ISIN: US22663K1079
Crinetics Pharmaceuticals Inc
CRNX
LISTED
NASDAQ
Crinetics Pharmaceuticals to Report Third Quarter 2025 Financial Results on November 6, 2025
News Preview
SAN DIEGO, Oct. 06, 2025 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) today announced that it will report third quarter 2025 financial results on Thursday, November 6, 2025 after the market closes. Company management will host a conference call at 4:30 p.m. ET to discuss financial results and provide a business update....
Themefolio
Profiler
Peergroup
© Globe Newswire
06.10.2025
ISIN: US09077A1060
Biomea Fusion Inc
BMEA
LISTED
NASDAQ
Biomea Fusion Announces Positive 52-Week Results from Phase II COVALENT-111 Study in Type 2 Diabetes Demonstrating Non-Chronic Treatment with Icovamenib Benefits Two Distinct Patient Populations
News Preview
SAN CARLOS, Calif., Oct. 06, 2025 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. (“Biomea” or “Biomea Fusion” or “the Company”) (Nasdaq: BMEA), a clinical-stage diabetes and obesity company, today announced positive 52-week results from its Phase II COVALENT-111 study evaluating the efficacy, safety, and tolerability of icovamenib in patients with type...
Themefolio
Profiler
Peergroup
© Globe Newswire
06.10.2025
ISIN: US29446K1060
Equillium Inc
EQ
LISTED
NASDAQ
Equillium Announces Leadership and Corporate Updates
News Preview
LA JOLLA, Calif., Oct. 06, 2025 (GLOBE NEWSWIRE) -- Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company leveraging a deep understanding of immunobiology to develop novel therapeutics to treat severe autoimmune and inflammatory disorders, today announced changes to its Board of Directors (BoD) and senior leadership, and other corp...
Themefolio
Profiler
Peergroup
© BusinessWire
06.10.2025
ISIN: US02155H2004
Altimmune Inc
ALT
LISTED
NASDAQ
FINAL DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Altimmune
News Preview
Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Altimmune, Inc. (“Altimmune” or the “Company”) (NASDAQ: ALT) and reminds investors of the October 6, 2025 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company.
Faruqi &...
Themefolio
Profiler
Peergroup
© BusinessWire
06.10.2025
ISIN: US60855R1005
Molina Healthcare Inc
MOH
LISTED
NYSE
Law Offices of Howard G. Smith Encourages Molina Healthcare, Inc. (MOH) Shareholders To Inquire About Securities Fraud Class Action
News Preview
Law Offices of Howard G. Smith announces that a class action lawsuit has been filed on behalf of investors who purchased Molina Healthcare, Inc. (“Molina” or the “Company”) (NYSE: MOH) securities between February 5, 2025 and July 23, 2025, inclusive (the “Class Period”). Molina investors have until December 2, 2025 to file a lead plaintiff motion....
Themefolio
Profiler
Peergroup
© BusinessWire
06.10.2025
ISIN: US60855R1005
Molina Healthcare Inc
MOH
LISTED
NYSE
DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Molina Healthcare
News Preview
Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Molina Healthcare, Inc. (“Molina” or the “Company”) (NYSE: MOH) and reminds investors of the December 2, 2025 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company.
Faruqi...
Themefolio
Profiler
Peergroup
© PR Newswire
06.10.2025
ISIN: US03237H1014
Amylyx Pharmaceuticals Inc
AMLX
LISTED
NASDAQ
Kuehn Law Encourages Investors of Amylyx Pharmaceuticals, Inc. to Contact Law Firm
News Preview
NEW YORK, Oct. 6, 2025 /PRNewswire/ -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of Amylyx Pharmaceuticals, Inc. (NASDAQ: AMLX) breached their fiduciary duties to shareholders. ...
Themefolio
Profiler
Peergroup
© ActuNews
06.10.2025
ISIN: FR0000061129
Boiron SA
BOI
LISTED
EURONEXT
BOIRON : CALENDRIER PRÉVISIONNEL DES PROCHAINES PUBLICATIONS ET ÉVÈNEMENTS 2026
News Preview
Le calendrier prévisionnel des prochaines publications et événements pour l'année 2026 est le suivant :
Publications
Date de publication
(après bourse)
Chiffre d'affaires et résultats annuels 2025
Jeudi 2 avril 2026
Assemblée Général...
Themefolio
Profiler
Peergroup
© ACCESSWIRE
06.10.2025
ISIN: US18507C1036
Clearpoint Neuro Inc
CLPT
LISTED
NASDAQ
ClearPoint Neuro Announces Expanded International Clearances for Key Therapy Delivery Product; Now Totaling 34 Countries Worldwide
News Preview
The clearly established history across global regulatory bodies is expected to de-risk BioPharma partners' pathways towards achieving global scale and standardization. SOLANA BEACH, CALIFORNIA / ACCESS Newswire / October 6, 2025 / ClearPoint Neuro, Inc. (NASDAQ:CLPT) (the "Company"), a global device, cell, and gene therapy-enabling compan...
Themefolio
Profiler
Peergroup
Long/Short | Fractionals | Margin | Hedge · 4 powerful Trading App | MT4.MT5.ACTIVTRADER | TradingViewplus
More information, click here
More sector specific news
Your Press Release is missing or you want share news over GICS11? Drop us a line.
